 |
|
|
|
 |
| JULY 16 ,
2009 | ISSUE NUMBER 107 VOL 6 |
Profile
Daiichi Chief Talks Effient
Lilly and Daiichi can breathe easier knowing that their new blood thinner Effient has FDA’s seal of approval. But what exactly separates the drug from Plavix and why all the excitement? Pharm Exec talks to Daiichi Sankyo President and CEO Joseph P. Pieronion to find out more.
New Media
Novo Nordisk Launches Branded Twitter Campaign
Social networking has been slow to permeate the pharmaceutical industry, and the response has been mixed at best. Novo Nordisk is gambling that Twitter might be the right tool for the job and latching racer Charlie Kimball’s name to the campaign might get them the Tweets they need to boost awareness of Levemir.
Global
Pharma Accused of Keeping Good Generics Down
EU Commission claims pharma firms are violating antitrust laws by delaying generic entry through shady practices, including false safety claims and reverse payment settlements.
Opinion
Playing Spot the Healthcare Lobbyist
National Public Radio has posted a photograph taken late last month during the first Congressional hearings on the trillion-dollar healthcare reform legislation. It shows not the 22 members of the Senate Committee on Health, Education, Labor and Pensions who were the presumptive stars of the occasion, but the audience.
|
 |
|  OncoMed Pharmaceuticals appointed Sunil Patel to senior vice president, corporate development // DOR BioPharma appointed Christopher P. Schnittker to vice president of administration and controller // Brecon Pharmaceuticals named Peter Belden executive vice president and managing director // Covington & Burling made Demetrios L. Kouzoukas the firm’s healthcare and food and drug practice groups as of counsel //
Progenitor Cell Therapy appointed Daryl LeSueur to vice president of manufacturing operations // Amgen appointed Rebecca M. Henderson to board of directors
// Covance appointed Steven M. Michael, MD, as vice president and chief scientific officer of Global Bioanalytical Services // Core-Create named Jin Li Frick managing director, Paul Maurer creative director of copy, Jennifer Philburn editorial manager/copywriter, Paul Moorcroft financial controller, and Michael Westhafer, MD, associate medical director of Alpha & Omega Worldwide // Poniard Pharmaceuticals appointed Gary A. Lyons to board of directors
|
 |
|
|
|
July
30–31 CBI’s
4th Clinical Supply Chain Management Conference,
Princeton, NJ
August
11–22 3rd Annual Forum on Tracking State Laws and Aggregate Spend,
Arlington, VA
September
14–15 4th Annual Forum on Educational Grants for the Bio/Pharmaceutical Industry,
Philadelphia, PA
September
21–24 5th
Annual Process Excellence Week for the Service & Transactional
World, Chicago, IL
October
5–7 BioNetwork
2009: The 7th Annual Pharmaceutical-Biotech Partnering
Conference, Laguna Niguel, California |
|
|
|
 |
|
 |
|
 |
| Should the Department of Justice end pharma’s tactic of paying off other firms to postpone generic competition? |
|
|
|
|
You are subscribed to ModernMedicine.com.
To unsubscribe, click here
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
